直接口服抗凝药与华法林相关脊髓硬膜外血肿的药物警戒研究
基于FAERS数据库2003年Q4至2025年Q2的回顾性比例失衡分析,共识别143例脊髓硬膜外血肿报告,华法林83例、利伐沙班28例、阿哌沙班25例、达比加群7例,所有药物均显示显著信号,华法林信号最强(ROR 29.2,95%CI 22.9-37.1),其次为利伐沙班(ROR 8.09)、达比加群(ROR 5.75)和阿哌沙班(ROR 4.78)。
要点
- 华法林相关SEH信号最强(ROR 29.2),利伐沙班次之(ROR 8.09)。
- 华法林患者平均年龄62岁,DOAC使用者75-76岁。
- 死亡病例中华法林9例、利伐沙班8例。
核心结论
- 华法林和DOACs均与脊髓硬膜外血肿报告存在比例失衡信号,华法林和利伐沙班信号较强。
- 因自发报告数据库的固有局限性,这些发现应视为假设生成而非因果关系。
研究设计与样本
- 回顾性比例失衡分析,使用FDA不良事件报告系统(FAERS)2003年Q4至2025年Q2数据。
- 分析华法林、利伐沙班、阿哌沙班和达比加群相关的SEH报告。
- 信号检测采用报告比值比(ROR)、比例报告比(PRR)和Yates校正卡方分析,信号显著定义为n>3、χ2>4且PRR>2。
主要发现
- 共识别143例SEH报告:华法林83例,利伐沙班28例,阿哌沙班25例,达比加群7例。
- 所有药物均显示显著比例失衡信号:华法林ROR 29.2(95%CI 22.9-37.1),利伐沙班ROR 8.09,达比加群ROR 5.75,阿哌沙班ROR 4.78。
- 华法林患者平均年龄62岁,DOAC使用者75-76岁。
- 死亡病例:华法林9例,利伐沙班8例。
- 抗凝最常见适应证为心房颤动。
关键数值与推荐
- 信号显著标准:n>3、χ2>4且PRR>2。
- 华法林ROR 29.2(95%CI 22.9-37.1),利伐沙班ROR 8.09,达比加群ROR 5.75,阿哌沙班ROR 4.78。
临床怎么用
- 临床医生应知晓华法林和DOACs均与SEH报告信号相关,华法林和利伐沙班信号较强。
- 对接受抗凝治疗尤其是华法林或利伐沙班的患者,出现脊髓硬膜外血肿症状时应保持警惕。
局限性
- 自发报告数据库存在固有局限性,包括报告偏倚、混杂因素和缺乏分母数据。
- 研究结果应解释为假设生成而非因果关系。
- 需要进一步对照研究确定真实发病率和比较风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spontaneous spinal epidural hematoma (SEH) is a rare but potentially catastrophic condition that may be worsened by anticoagulation. We evaluated reporting patterns and signal strength of SEH associated with warfarin and DOACs using pharmacovigilance database analysis. METHODS: A retrospective disproportionality analysis was conducted using the FDA Adverse Event Reporting System (FAERS) from Q4/2003 to Q2/2025. Reports of SEH associated with warfarin, rivaroxaban, apixaban, and dabigatran were analyzed. Signal detection employed Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and chi-squared analysis with Yates' correction. A signal was significant if n > 3, χ2 > 4, and PRR > 2. RESULTS: A total of 143 SEH reports were identified. Warfarin accounted for 83 cases, rivaroxaban 28, apixaban 25, and dabigatran 7. All demonstrated significant disproportionality signals. Warfarin showed the strongest signal (ROR 29.2, 95% CI 22.9-37.1), followed by rivaroxaban (ROR 8.09), dabigatran (ROR 5.75), and apixaban (ROR 4.78). Warfarin patients were younger (mean 62 years) than DOAC users (75-76 years). Mortality occurred in 9 warfarin and 8 rivaroxaban cases. Atrial fibrillation was the most frequent indication for anti-coagulation. CONCLUSIONS: This pharmacovigilance study identified disproportionate reporting signals for spinal epidural hematoma across warfarin and DOACs, with stronger signals observed for warfarin and rivaroxaban. Given the inherent limitations of spontaneous reporting databases, these findings should be interpreted as hypothesis-generating rather than causal. Further controlled studies are needed to determine true incidence and comparative risk.
引用
- Porwal M, Stegamat N, Reddy V, et al. Pharmacovigilance study of spinal epidural hematoma reports associated with direct oral anticoagulants and warfarin. Acta Neurochir (Wien). 2026. PMID: 42062621. doi:10.1007/s00701-026-06860-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。